Corbus Pharmaceuticals
CRBP
80 hedge funds and large institutions have $62.5M invested in Corbus Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 29 reducing their positions, and 21 closing their positions.
13% more capital invested
Capital invested by funds: $55.4M → $62.5M (+$7.13M)
7% less funds holding
Funds holding: 86 → 80 (-6)
11.23% less ownership
Funds ownership: 85.29% → 74.06% (-11%)
14% less call options, than puts
Call options by funds: $138K | Put options by funds: $161K
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
41% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$598K |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$561K |
| 3 |
Millennium Management
New York
|
+$418K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$402K |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$329K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.59M |
| 2 |
Renaissance Technologies
New York
|
-$1.39M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.22M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$998K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$676K |
CRBP Hedge Fund Activity: Q2 2025 in Review
80 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2025, worth a combined $62.5M — up 13% from $55.4M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CRBP and 15 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 17 added.
The largest buyer was Morgan Stanley, adding an estimated $598K. The largest seller was BlackRock, cutting an estimated $3.59M.
- 80 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2025, down from 86 in Q1 2025.
- Funds reported $62.5M of Corbus Pharmaceuticals stock for Q2 2025, up 13% quarter-over-quarter.
- 15 funds opened new Corbus Pharmaceuticals positions in Q2 2025 and 21 closed out, a net change of -6 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2025 was Morgan Stanley, an estimated $598K added.
- The largest Corbus Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $3.59M sold.
Based on aggregated 13F filings for Q2 2025.